Jeevan Scientific Technology Limited has submitted a regulatory disclosure to BSE Limited regarding the successful completion of a United States Food and Drug Administration (USFDA) inspection at its bioanalytical facility in Manikonda, Hyderabad.
The USFDA inspection was conducted to review Bioanalytical/Bioequivalence (BA/BE) studies as well as the company's operations, systems, and procedures. The inspection period spanned from July 20, 2026, to July 24, 2026.
The inspection concluded with zero observations (no Form 483s issued). The USFDA inspectors provided positive feedback, noting that the entire JSTL team is well trained, knowledgeable, and experienced with international regulatory requirements and good practices. They also confirmed that the organization operates within an adequately designed infrastructure and is compliant with all applicable regulations.